Journal
FRONTIERS IN ENDOCRINOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fendo.2021.599586
Keywords
acquired resistance; breast cancer; endocrine resistance; endocrine therapy; estrogen receptor; de novo resistance
Categories
Funding
- Mizan Tepi University
- Addis Ababa University
- Armauer Hansen Research Institute (AHRI)
Ask authors/readers for more resources
The estrogen receptor is crucial in the treatment of estrogen receptor-positive breast cancer, with endocrine resistance posing a challenge. Combining drugs that target different signaling pathways and coregulatory proteins with endocrine therapy may offer a novel therapeutic approach to combat endocrine resistance.
The estrogen receptor is a vital receptor for therapeutic targets in estrogen receptor-positive breast cancer. The main strategy for the treatment of estrogen receptor-positive breast cancers is blocking the estrogen action on estrogen receptors by endocrine therapy but this can be restricted via endocrine resistance. Endocrine resistance occurs due to both de novo and acquired resistance. This review focuses on the mechanisms of the ligand-dependent and ligand-independent pathways and other coregulators, which are responsible for endocrine resistance. It concludes that combinatorial drugs that target different signaling pathways and coregulatory proteins together with endocrine therapy could be a novel therapeutic modality to stop endocrine resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available